TOP2A

TOP2A Molekülinformation

Englischer Name	Topoisomerase (DNA) II alpha	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1	Target-Alias	EC:5.6.2.2，EC 5.6.2.2，TOP2A，DNA topoisomerase 2-alpha，DNA topoisomerase II， alpha isozyme，DNA Topoisomerase II Alpha，Topoisomerase (DNA) II Alpha 170kDa，TOP2，DNA Topoisomerase (ATP-Hydrolyzing)，DNA Topoisomerase II， 170 KD，EC 5.99.1.3，TP2A，DNA Gyrase
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Topoisomerase (DNA) II alpha
Target-Alias	EC:5.6.2.2，EC 5.6.2.2，TOP2A，DNA topoisomerase 2-alpha，DNA topoisomerase II， alpha isozyme，DNA Topoisomerase II Alpha，Topoisomerase (DNA) II Alpha 170kDa，TOP2，DNA Topoisomerase (ATP-Hydrolyzing)，DNA Topoisomerase II， 170 KD，EC 5.99.1.3，TP2A，DNA Gyrase
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Approved

TOP2A Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
Tag Free (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TOA-H5117	Human	E. coli	Human TOP2A / TOP2 Protein, Tag Free				In den Warenkorb legen

Gesamtmenge1

TOP2A Molekülhintergrund

DNA topoisomerase 2-alpha (TOP2A) is also known as DNA topoisomerase II, alpha isozyme and TOP2. It is a topoisomerase which control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation. Also it is the targets of anti-cancer drugs that cause treatment-related leukemias with balanced translocations.

TOP2A Molekülalias

TOP2A,TOP2,DNA topoisomerase 2-alpha,DNA topoisomerase II,alpha isozyme

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Novobiocin Sodium		Phase 1 Clinical		Bacterial Infections; Neoplasms; Solid tumours	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Etoposide phosphate	BMY-40481	Approved	Bristol-Myers Squibb Company	Etopophos	United States	Lymphoma, Non-Hodgkin; Multiple Myeloma; Testicular Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hodgkin Disease; Small Cell Lung Carcinoma	Cheplapharm Arzneimittel Gmbh	1996-05-17	Adrenocortical Carcinoma; Breast Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; CNS Embryonal Tumor; Germinoma; Hodgkin Disease; Kidney Neoplasms; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neoplasms, Gonadal Tissue; Neoplasms, Plasma Cell; Neuroblastoma; Neutropenia; Ovarian Neoplasms; Plasmacytoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma; Sarcoma, Ewing; Small Cell Lung Carcinoma; Solid tumours; Testicular Neoplasms; Thrombocytopenia; Uterine Cervical Neoplasms	Details